Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07209358 · ClinicalTrials.gov registry record · NA

EDX110 Randomized Control Trial for Treatment of DFUs

A NA study of Diabetic Foot Ulcer and Wound Heal, sponsored by ConvaTec.

Recruiting
Registry status
NA
Development phase
298
Enrollment target
4
Study locations

NCT07209358: Recruiting NA study of Diabetic Foot Ulcer and Wound Heal, sponsored by ConvaTec.

NCT07209358 is a NA study of Diabetic Foot Ulcer and Wound Heal that is actively recruiting participants, run by ConvaTec. The registered enrollment target is 298 participants, above the 251-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (19% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07209358, a NA study of Diabetic Foot Ulcer and Wound Heal, is actively recruiting participants, sponsored by ConvaTec.

RECRUITING
Registry status
NA
Development phase
298 participants
Enrollment target
4
Study locations

Study Summary

Prospective, multi-centered, observer blinded, pre-market study, 1:1 randomized control trial, to determine if addition of EDX110 dressing system to standard of care leads to an improvement in diabetic foot ulcers healing compared to just using standard of care.

Primary Outcome

Incidence of complete wound closure at 16 weeks in participants with DFU who are receiving standard of care (SOC) versus participants receiving EDX110 and SOC. Wound closure is defined as 100% reepithelialization of the wound without drainage.

Interventions

  • DEVICE EDX110

Study Locations (4)

California

  • Clemente Clinical Research - Santa Ana
  • ILD Research Center - Vista

Arizona

  • Axentra Bio - Phoenix

Texas

  • Futuro Clinical Trials - McAllen

Trial Details

FieldValue
Enrollment Target 298 participants
Start Date 2025-10-30
Est. Completion 2026-12-31
Phase NA
ConvaTec

17 total trials

What NCT07209358 shows while recruiting

NCT07209358 is an interventional study that assigns participants to a tested intervention. The registered 298 participants enrollment target is mid-sized for trials with a published cap, above the 251-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (19% higher).

The record links to 2 conditions, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 1 intervention - of which EDX110 is the first listed.

NCT07209358 reports a single indexed study location in California, Arizona, Texas.

Frequently Asked Questions

What is clinical trial NCT07209358 about?

NCT07209358 is a clinical study titled "EDX110 Randomized Control Trial for Treatment of DFUs". Prospective, multi-centered, observer blinded, pre-market study, 1:1 randomized control trial, to determine if addition of EDX110 dressing system to standard of care leads to an improvement in diabetic foot ulcers healing compared to just using standard of care.

What is the current status of trial NCT07209358?

This trial is currently recruiting. It is a NA study. The enrollment target is 298 participants. The study started on 2025-10-30. Estimated completion is 2026-12-31.

What conditions does trial NCT07209358 study?

This clinical trial studies the following conditions: Diabetic Foot Ulcer, Wound Heal.

What interventions are being tested in trial NCT07209358?

The interventions under investigation include: EDX110 (DEVICE).

Who is sponsoring clinical trial NCT07209358?

This trial is sponsored by ConvaTec, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07209358 being conducted?

This trial has 4 study locations across Arizona, California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Foot Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07209358's enrollment target sits among peer trials

298 11th of 67 higher than 57 of 67 other Diabetic Foot Ulcer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetic Foot Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06305624 · 298 participants · NA

    Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease

  • NCT06754215 · 298 participants · NA

    Smoking Cessation Intervention Development for Homeless Youth

  • NCT06780111 · 298 participants · Phase 1

    Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

  • NCT06309160 · 297 participants · NA

    COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07209358, the US trial registry maintained by the National Library of Medicine. NCT07209358 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.